Population
Two cases with heterozygous mutation in the LDLR promoter c.-135C>G
Design
Case report
Key result
Dual lipid-lowering therapy achieved a significant reduction in cholesterol levels in two patients with a heterozygous LDLR promoter mutation who had failed lovastatin monotherapy.
Authors
Loading...
Hypothesis-generating for dual therapy in LDLR promoter mutations; prospective trials needed before practice change.
Case Report (n=2)
Dual lipid-lowering therapy successfully reduced cholesterol levels in two patients with familial hypercholesterolemia due to a heterozygous LDLR promoter mutation who had previously failed lovastatin monotherapy.
Figueroa-Buitrago et al. (2024) conducted a case report in Familial hypercholesterolemia (n=2). Dual lipid-lowering therapy (alirocumab+rosuvastatin or atorvastatin+ezetimibe) vs. Lovastatin monotherapy was evaluated on Reduction in cholesterol levels. Dual lipid-lowering therapy achieved a significant reduction in cholesterol levels in two patients with a heterozygous LDLR promoter mutation who had failed lovastatin monotherapy.